Association between cohabitation status and allocation to intensive therapy and HSCT in first CR
| Cohabitation status . | Patients, outcomes, n (%) . | OR* (95% CI) . | aOR† (95% CI) . | aOR†‡ (95% CI) . |
|---|---|---|---|---|
| Intensive therapy | ||||
| All patients | 3243 | |||
| Cohabitating | 2056 (57.5) | 1.0 | 1.0 | 1.0 |
| Living alone | 1187 (37.2) | 0.44 (0.38-0.51) | 0.58 (0.46-0.73) | 0.60 (0.46-0.77) |
| Age <60 y | ||||
| Cohabitating | 622 (94.5) | 1.0 | 1.0 | 1.0 |
| Living alone | 251 (90.8) | 0.57 (0.33-0.99) | 0.66 (0.35-1.26) | 0.95 (0.46-1.95) |
| Age ≥60 y | ||||
| Cohabitating | 1434 (41.2) | 1.0 | 1.0 | 1.0 |
| Living alone | 936 (22.8) | 0.42 (0.35-0.50) | 0.60 (0.46-0.78) | 0.61 (0.46-0.81) |
| Trial inclusion | ||||
| Patients receiving intensive chemotherapy | 1623 | |||
| Cohabitating | 1182 (31.6) | 1.0 | 1.0 | 1.0 |
| Living alone | 441 (28.6) | 0.86 (0.68-1.10) | 0.88 (0.68-1.12) | 0.90 (0.70-1.17) |
| CR | ||||
| Patients receiving intensive chemotherapy | 1623 | |||
| Cohabitating | 1182 (70.6) | 1.0 | 1.0 | 1.0 |
| Living alone | 441 (72.8) | 1.11 (0.87-1.42) | 1.06 (0.81-1.37) | 1.06 (0.81-1.39) |
| HSCT in first CR | ||||
| HSCT candidates§ | 964 | |||
| Cohabitating | 702 (19.0) | 1.0 | 1.0 | 1.0 |
| Living alone | 262 (11.8) | 0.57 (0.38-0.87) | 0.46 (0.28-0.76) | 0.47 (0.28-0.78) |
| Cohabitation status . | Patients, outcomes, n (%) . | OR* (95% CI) . | aOR† (95% CI) . | aOR†‡ (95% CI) . |
|---|---|---|---|---|
| Intensive therapy | ||||
| All patients | 3243 | |||
| Cohabitating | 2056 (57.5) | 1.0 | 1.0 | 1.0 |
| Living alone | 1187 (37.2) | 0.44 (0.38-0.51) | 0.58 (0.46-0.73) | 0.60 (0.46-0.77) |
| Age <60 y | ||||
| Cohabitating | 622 (94.5) | 1.0 | 1.0 | 1.0 |
| Living alone | 251 (90.8) | 0.57 (0.33-0.99) | 0.66 (0.35-1.26) | 0.95 (0.46-1.95) |
| Age ≥60 y | ||||
| Cohabitating | 1434 (41.2) | 1.0 | 1.0 | 1.0 |
| Living alone | 936 (22.8) | 0.42 (0.35-0.50) | 0.60 (0.46-0.78) | 0.61 (0.46-0.81) |
| Trial inclusion | ||||
| Patients receiving intensive chemotherapy | 1623 | |||
| Cohabitating | 1182 (31.6) | 1.0 | 1.0 | 1.0 |
| Living alone | 441 (28.6) | 0.86 (0.68-1.10) | 0.88 (0.68-1.12) | 0.90 (0.70-1.17) |
| CR | ||||
| Patients receiving intensive chemotherapy | 1623 | |||
| Cohabitating | 1182 (70.6) | 1.0 | 1.0 | 1.0 |
| Living alone | 441 (72.8) | 1.11 (0.87-1.42) | 1.06 (0.81-1.37) | 1.06 (0.81-1.39) |
| HSCT in first CR | ||||
| HSCT candidates§ | 964 | |||
| Cohabitating | 702 (19.0) | 1.0 | 1.0 | 1.0 |
| Living alone | 262 (11.8) | 0.57 (0.38-0.87) | 0.46 (0.28-0.76) | 0.47 (0.28-0.78) |
CI, confidence interval; SES, socioeconomic status.
Crude.
Adjusted for age, sex, and clinical factors, including white blood cell count, cytogenetic risk group, World Health Organization performance status, type of leukemia (de novo, secondary, or therapy-related AML), and comorbidity.
Adjusted for SES, including income, educational level, and occupation.
Patients excluded from analysis: not reaching CR, n = 2038; favorable cytogenetic risk group, n = 84; age >70 years, n = 157.